Topics

Novartis, Amgen halt clinical testing of BACE inhibitor umibecestat in Alzheimer's disease prevention after patients worsened http://www.firstwordpharma.com/node/1652605?tsid=28®ion_id=6#axzz5tOBYUG7c …

18:01 EDT 11 Jul 2019 | FirstWord Pharma

Novartis, Amgen halt clinical testing of BACE inhibitor umibecestat in Alzheimer's disease prevention after patients worsened http://www.firstwordpharma.com/node/1652605?tsid=28&region_id=6#axzz5tOBYUG7c …

Original Article: Novartis, Amgen halt clinical testing of BACE inhibitor umibecestat in Alzheimer's disease prevention after patients worsened http://www.firstwordpharma.com/node/1652605?tsid=28®ion_id=6#axzz5tOBYUG7c …

NEXT ARTICLE

More From BioPortfolio on "Novartis, Amgen halt clinical testing of BACE inhibitor umibecestat in Alzheimer's disease prevention after patients worsened http://www.firstwordpharma.com/node/1652605?tsid=28®ion_id=6#axzz5tOBYUG7c …"

Quick Search

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...